Clinical Trial: A Phase 1 Study of WVE-007 in Adults Living with Overweight or Obesity

U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT06842186) titled 'A Phase 1 Study of WVE-007 in Adults Living with Overweight or Obesity' on Jan. 29.

Brief Summary: The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of WVE-007 when administered subcutaneously (SC) as single ascending doses in adults who are affected by overweight or obesity.

Study Start Date: Jan. 31

Study Type: INTERVENTIONAL

Condition: Obesity and Overweight

Intervention: DRUG: WVE-007

Stereopure siRNA oligonucleotide

Recruitment Status: RECRUITING

Sponsor: Wave Life Sciences Ltd.

Disclaimer: Curated by HT Syndication....